Children suffer fewer transplant complications than adults. In contrast it has been reported that they fare worse than adults after immunosuppressive treatment. It was the goal of this study to compare outcome in patients younger or older than 16 years of age receiving either primary treatment of severe aplastic anemia using an HLA-identical sibling transplant (SCT) if a donor was available or immunosuppression using ATG (IS) with or without other drugs after 1990 and reported to the EBMT (EBMT Aplastic Anemia Working Party database as of Oct.2001) . 674 adult patients (age > 16 years) received SCT from an HLA-identical sibling and 386 received ATG-based IS. 383 pediatric patients (<= 16 years) received SCT from an HLA-identical sibling and 106 received ATG-based IS. 24 pediatric patients and 112 adult patients were grafted with peripheral blood stem cells. Median age of the pediatric patients was 10.0 years (0-16) in the SCT group and 9.8 years (0 -16) in the IS group and of the adult patients age was 25. 1 (16-63.4) for for IS. Median interval between diagnosis and treatment of the pediatric SCT patients was 76.5 days and 31 days days in IS patients and of the adult patients was 99 days in the SCT group and 37 days in IS group. Main outcome was overall survival. Survival at 5 years after SCT was 86% (82% -90%) in children and 71% (67% -74%) in adults (p<0.01). After IS survival at 5 years was 78% (69% -88%) in children and 83% (79% -88%) in adults and (p=0.32). The probability of survival in children was improved after HLAidentical sibling transplants as compared to adults but survival probability after IS treatment was similar. There is no evidence that children respond differently to ATG treatment than adults.
Conclusion

C. Steward
The talks in this session demonstrate a medical technology in transition. The past decade has brought major technical improvements in stem cell transplantation which now enable almost all patients to be transplanted (from matched, mismatched or haploidentical donors), and are allowing improved results and the exploration of new areas of transplantation. However, in some diseases -particularly those discussed in this session -transplant morbidity and mortality remain significant. The great challenge in genetic diseases will be to correctly evaluate the role of SCT as genetic and proteomic knowledge advances, bringing with it new drugs and therapies (including gene, enzyme and substrate deprivation therapies). For years arguments have raged between advocates and opponents of SCT for haemoglobinopathies. The next few years will see similar debates in relation to autoimmune diseases, aplastic anaemia, congenital neutropenia and various mucopolysaccharidoses. It will be important to develop online protocols for the management of these conditions, outlining best practice and responding rapidly to new developments. These should help the physician faced with these rare and complex disorders, including advice on genetic and other investigation, the range of potential treatments, complications peculiar to each disease and standardised approaches to transplant conditioning and long term assessment / management. A good example from this session is provided by HLH: it is now known that disease in approximately 50% of patients is caused by defects in perforin, allowing siblings being considered as donors to be screened for occult disease. Yet many BMT physicians will be unaware of this development. The metabolic disease guidelines discussed in this session are a first step. Developing similar and more detailed guidelines / protocols for other genetic diseases will be an invaluable future role for the working parties of the EBMT.
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Restoration of t cell immunity after stem cell transplantation E. Roosnek (Geneva, CH) After SCT, the function of most hematological lineages is proportional to the numbers in the blood. However, this rule is not valid for T°cells. Even when their number has been restored to normal values, T cell immune deficiency may persist. The reason for this is that once the T cell compartment has been annihilated through the transplant procedure, it is reconstituted initially through expansion of mature T cells. Because this pathway restores T cell numbers without increasing T cell receptor diversity, the initial wholes in the repertoire will persist The first wave of reconstitution is usually followed by second phase of T cell regeneration through the thymic pathway, which can be assessed by the increase of CD4+CD45RA+RO-naive T cells in the blood. Our studies show that the first CD4+CD45RA+RO-thymic emigrants appear after 3-6 months after SCT. While young patients reconstituted swiftly, in older patients, the recovery of normal numbers of naive CD4+ T cells could take several years. The thymic emigrants were responsible for the restoration of the T cell repertoire and consequently, for the patient's capacity to respond to vaccinations. Patients without a significant thymic rebound at the moment of vaccination (CD4+CD45RA+RO-T cells < 30 L) did not respond, or responded only marginally even after three boosts with TT. These findings emphasize the crucial role of the thymus in the restoration of immunity after SCT.
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B cell immunity after allogeneic hematopoietic cell transplantation J. Storek (Seattle, USA) Infections follow hematopoietic cell transplantation (HCT) for more than one year.1, 2 This appears to be due in part to Blymphocytopenia.3 Low IgA and IgG2 levels predispose transplant recipients to infections, primarily those due to Streptococcus pneumoniae or Haemophilus influenzae. [4] [5] [6] [7] Theoretically, low antibody levels may predispose patients also to relapses of primary malignancy or secondary malignancies.8-10 B cell counts are near-zero in the first month after myeloablative HCT. They reach normal adult levels within approximately 6 month after autologous HCT, 9 months after allogeneic HCT without GVHD and ≥12 months after allogeneic HCT with GVHD. The delay is due to the suppression of marrow B-lymphopoiesis by GVHD or its treatment.11 Circulating B cells have phenotype and repertoire similar to those of neonatal B cells, i.e., IgDhigh, CD38high, CD1c+, forward scatterhigh and low frequency of somatic mutations. Upon in vitro polyclonal stimulation, B cell proliferation and IgM production are near-normal whereas IgG and IgA production is low. This is most likely due to the low frequency of circulating isotype-switched or somatically mutated B cells, which in turn may be related to the relative absence of germinal centers in the spleen and lymph nodes. The cause of the relative lack of germinal centers is unknown (shortage of helper T cells or follicular dendritic cells?). B cells are of donor origin (after myeloablative, T cell replete HCT). Plasma cells appear to be primarily of host origin in the first several months after grafting. They are gradually replaced by plasma cells derived from donor B cells over the subsequent months to years. Whether the donor B cells originate from the grafted stem cells or B cells has not been directly studied. Circumstantial evidence suggests that by [4] [5] [6] months after grafting the majority of B cells have been generated de novo (from stem cells). Antibody levels and antibody responses to immunization reflect the number and function of B cells in concert with plasma cells, helper T cells, follicular dendritic cells and other cells involved in the generation of antibodies. In the first month after grafting, total IgM, IgG and IgA levels fall and nadir near the low normal limit. They return to the normal range over the subsequent months to years, IgM first, and IgG2 and IgA last. Specific antibody levels (e.g. against pneumococci) after grafting are higher in patients with high antibody levels pretransplant transplanted from donors with high antibody levels pretransplant. In case of recall protein antigens and polysaccharide-protein conjugate antigens, the posttransplant antibody levels can be substantially increased by immunizing the donor pretransplant and the recipient peritransplant/early posttransplant. Improvement of B cell immunity will likely come from 1. improved understanding and modulation of the presumed defect of naïve to memory B cell differentiation, 2. improved understanding and modulation of the suppressive effect of GVHD on B-lymphopoiesis, or 3. the use of current vaccines and, in particular, future (more immunogenic) pneumococcal and cancer vaccines for the immunization of both the donor and the recipient pretransplant (several doses?) and boosting the recipient peritransplant/early posttransplant. Lymphocyte infusions will likely be of no or limited benefit, as graftings PBSCs instead of marrow (the former containing 10-times more lymphocytes) does not improve antibody immunity posttransplant. Intravenous immunoglobulin is associated with only modest short-term benefit and with the risk of hampering the reconstitution of endogeneous antibodies. Reconstitution of a mature T-cell compartment following allogeneic stem cell transplantation relies on the generation of naive T-cells via the thymus. However, thymic function may be adversely affected by the transplant procedure itself. In this study we assessed thymic function in 63 pediatric recipients (11 haploidentical, 24 unrelated, 28 HLA-identical sibling donors) between 1 and 107 months post-transplant. Peripheral mononuclear cells were isolated at the respective time points and lysed with Proteinase K. A quantitative PCRassay measuring the frequencies of T-cell receptor recombination excision circles (TRECs) was used to determine the number of TREC+-cells per 105 T-cells. Values were calculated by comparing fluorescence intensity of the sample at a certain threshold cycle with that of an internal standard. Since only recent thymic emigrants carry TRECs with one copy per cell, TREC-values are a reliable indicator of thymic function. Thymic function was very low in the first year posttransplant but increased with time (1685 + 4140 vs. 10372 + 12703 TREC+ T-cells/105 T-cells before and after 12 months post-transplant, mean + SD). There was a tendency to higher TREC-values in recipients of T-cell depleted stem cell grafts before and after the first year post-transplant (significant between 12-24 months post-transplant). GvHD significantly suppressed thymic function, whereas a stem cell dose of >1e7 CD34/kgBW seemed to enhance thymic function significantly during the second year post-transplant. A significant difference in thymic function during the first year post-transplant was observed in patients with nonmalignant and malignant diseases (4691 + 6294 vs. 182 + 631 TREC+ T-cells/105 Tcells, mean + SD). This difference became less prominent after 12 months (11891 + 10953 vs. 8151 + 2925 TREC+-cells/105 T-cells, mean + SD).
In conclusion, thymic function is severely affected by allogeneic stem cell transplantation, but, at least in children, recovers with time. Malignant disease is an unfavorable prognostic factor for thymic function in the first year posttransplant, probably due to heavier pretreatment. Further studies will identify factors that positively influence thymic function, e.g. higher stem cell dose or protection from radio-, chemotherapy induced thymic injury. An increased thymic function in the early post-transplant phase will accelerate T-cell reconstitution, thereby reducing transplant-related morbidity and mortality. 19/82 (23 %) patients were transplanted with PBPC and 62/82 (76%) with bone marrow and 1 case with cord blood as a transplant material. Fifty one patients are alive (62 %) and disease-free (median follow up was 1762 (range from 90 to 4776 days). 31/82 (38 %) died with different post-transplant complications from 7 to1615 days. 47/82 (57%) patients did not develope acute GVHD. Grade I of acute GVHD occurred in 17/82 patients (21 %), whereas grade II-IV in 18/82 (22 %). The monitoring of chimerism by PCR analysis of highly polymorphic microsatellite loci (STR-PCR) has become a routine diagnostic approach in patients since 1998. 39 patients and donors derived hematopoiesis were assessed twice weekly during first month post transplant and then usually in one month intervals. During these observation period we found stable full donor chimerism in 29 children (74%), stable mixed chimerism in 5 children (13%) and autologous recovery in 3 children (8%). 2/39 patients (5%) become mixed chimerism from full donor chimerism and died due to relapsed. Among patients who alive with stable mixed chimerism 40% to 90% of T cells were of donor origin. Monitoring of the dynamics of chimerism allowed rapid assessment of the response to therapy. In two haploidentical and one unrelated donor transplants there was a graft failure which prompted us to second successful transplantation.
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Engraftment and GvHD after transplantation of allogeneic, highly purified CD34+ stem cells in children P. Lang, R. Handgretinger, T. Klingebiel, M. Schumm, J. Greil, P.G. Schlegel, P. Bader, D. Niethammer (Tubingen, D; Memphis, USA; Frankfurt, Wurzburg, D) 96 pediatric patients with malignant (n=76) and nonmalignant(n=20) diseases were transplanted with highly purified CD34+ stem cells from unrelated donors (n=43) or from mismatched family donors (n=53). Median purity of CD34+ cells after immunomagnetic selection was 97.8%. Patients received a median number of 14x10E6 CD34+/kg with a wide range of 1-54.6x106/kg and with only 7.6x10E3 contaminating CD3+ T cells/kg. No posttransplant pharmacological GvHD prophylaxis was administered. Results: primary engraftment was observed in 84.4% of patients. Nonengraftment and rejection occurred in 6.2% and 9.4% respectively. Patients with nonengraftment had received significantly lower CD34+ doses than patients with primary engraftment. However, 13 patients could be regrafted by reconditioning and second CD34+ donation. Thus, incidence of final graft failure was 2%. 76 patients had no signs of acute GvHD (80%), 12 patients had GvHD grade I (12%) and 5 patients experienced GvHD grade II (5%). Severe GvHD 3 and 4 was observed in only 3 patients and was associated with HHV6 infections (3%). 7 of 76 evaluable patients had limited and transient chronic GvHD (9%). No extensive GvHD was observed. Incidence of GvHD was similar in both groups (unrelated versus mismatched family donors). No correlation was seen between the number of CD34+ and development of GvHD. Conclusions: incidence of GvHD was remarkably low in our pediatric patients, due to the extremely low number of Tcells. No negative effects of high CD34+ cell doses on the development of acute/chronic GvHD were observed. Thus, transplantation of high numbers of purified CD34+ with < 25 000 contaminating T-cells/kg leads to a safe engraftment and allows to prevent GvHD even in the case of mismatched donors.
Summary: Novel insights into mechanisms governing immune reconstitution after SCT Paul G Schlegel and Maarten JD van Tol
Haematopoietic stem cell transplantation (SCT) offers the only curative approach for patients with advanced haematologic malignancies and certain non-malignant diseases. However, the need for an human leukocyte antigen (HLA)-identical donor has presented major limitations to this therapeutic modality necessitating a search for alternative donors. Recent advances have revolutionized criteria for donor selection (Aversa et al., 1998) , with the development of new immunosuppressive agents, approaches towards anergizing antigen-specific T-cells (Blazar et al., 1998) , and techniques for positive selection of stem cells (Handgretinger et al., 2001) . Together, these have pushed the limitations of donor selection beyond HLA barriers. The kinetics and quality of immune reconstitution are now one of the prime factors that determine the long-term prognosis following stem cell transplantation. Novel techniques and their application to the field of immune reconstitution, notably CDR3 Size Spectratyping of T-cell subpopulations (Godthelp et al., 1999 ., Eyrich et al., 2002 , TREC analysis combined with telomere length analysis (Rufer et al., 2001 ) have greatly increased our understanding of the processes that regulate the re-emergence of the functional Tcell compartment post transplant.
Several recent studies have elucidated two separate pathways of T-cell regeneration that contribute to the emergence of novel T-cell compartment following T-cell depleted as well as non-depleted allogeneic grafts. First, mature T-cells inoculated in the graft may, under antigenic stimulation, expand in the host (Fry and Mackall, 2001) . The TCR diversity of these Tcells is skewed and limited by the number of T-cells in the initial inoculum. This pathway is generally referred to as peripheral expansion and predominates in the early phase following conventional bone marrow transplantation. This has been observed to be a persistent phenomenon in hosts with decreased thymic function, namely in adults or patients with intensive pretransplant chemotherapy. Second, de novo maturation of naive T-cells from bone marrow emigrants via passage through the thymus has been shown to occur after 3-6 months in children. This pathway allows for de novo generation of T-cell responses and plays a part in correcting the initially skewed repertoire (Roux et al., 2000 , Godthelp et al., 2001 . Although it is a prerequisite for the restitutio ad integrum of the T-cell compartment, this pathway is limited to patients with residual thymic function and is therefore dependent on a variety of factors, most notably age and pretransplant chemotherapy . Are there novel approaches towards improving or enhancing T-cell immunity during this critical period of 3-6 months ? Several strategies are currently being evaluated in preclinical models. They may include adoptive transfer of either ex vivo generated T cells with low alloreactivity, antigen-specific T cells or T cells that have been engineered to carry a suicide gene as a safety switch. Thymic maturation itself may be enhanced by the administration of specific cytokines (AbdulHai et al., 1996) . Emerging evidence points to IL-7 as one of the master regulators of peripheral T-cell homeostasis (Fry and Mackall, 2001 ). Alternatively, thymic epithelial injury may be inhibited by the timely application of keratinocyte growth factor (Min et al., 2002) . One or several of these approaches may ultimately prove to be beneficial in the clinical setting.
Introduction: Over the past decades, allogeneic stem cell transplantation (allo-SCT) has been performed with increasing success in children with particularly unfavorable acute leukemias. The success of this treatment modality is mainly affected by recurrence of the underlying disease. Although the benefits of immunotherapy for CML patients as treatment for relapse is well documented1,2 there are fewer reports of successful response in patients with acute leukemias3,4. Moreover, clinical response has mostly been associated with measurable graft-versus-host disease (GVHD), possibly due to high cell doses given in the situation of frank hematological relapse. However, there is evidence that low dose of donor Tcells may also induce efficient immunoresponse in patients with small leukemia burden to re-achieve long term remission5. We have recently shown in a study of 55 patients with acute leukemias that patients who demonstrate increasing amounts of autologous marrow repopulation (increasing mixed chimerism; in-MC) have a significantly enhanced risk of relapse (p<0.0001)6. Therefore we investigated whether frank hematological relapse could be prevented by withdrawal of CSA and/or by administration of low dose DLI (dosage: 10-4 to 10-6) on the basis of in-MC in a large prospective multi-center study. Patients: Between January 1996 and December 2001 191 allo-SCT have been performed in children with ALL in 13 pediatric transplant centers in Germany. Informed consent of patients and parents were appropriate was obtained according to institutional guidelines. All data were analyzed up to May 2002. Methods: Determination of individual hematopoietic chimerism in short time intervals (weekly during the first 100 days thereafter once a month) was performed by a semiquantitative PCR approach based on amplification of STR markers as described previously. Additional immunotherapy was offered to patients who developed in-MC posttransplant as described in detail elsewhere.7-8
Results: 18 patients were excluded either due to lack of informative markers (n=2) or because no regular posttransplant samples were sent to the laboratory. This left 173 patients open to be studied. During follow-up 110 patients showed complete chimerism (CC; n=64) or low level MC (LL-MC with a maximum of 1% autologous cells; n=46), 47 patients developed in-MC and 16 children showed decreasing MC (de-MC). Of the 47 patients with in-MC additional immunotherapy was offered to 32 patients whereas 15 patients with in-MC received no additional treatment. In the group of patients showing CC/LL-MC (n=110) during follow-up only 9 patients relapsed, whereas 27/47 patients with in-MC developed relapse (P<0.0001). Further analysis of the latter group of patients with in-MC showed, that 16/32 patients with additional immunotherapy responded to treatment, 13/16 remained in CCR, 3 patients died due to infections. In the group of patients with in-MC who received no additional treatment 11/15 relapsed, 3/15 rejected their graft and one patient died to TRM reasons. Only one patient survived after having rejected the graft. However, this patient received a second transplant. Altogether 16/32 patients with in-MC and additional treatment relapsed, whereas in the group of 15 patients with in-MC who did not receive prophylactic treatment 11/15 patients died due to relapse (P<0.0001). The event free survival (EFS) in the group of patients with in-MC and immunotherapy is 0.37 (n=32; SE: 0.09) vs. 0.0 in the group of patients without additional therapy (n=15; SE: 0.0) (P=0.0003). Severe GVHD was not seen in any patients who received immunotherapy. In addition, non of the 16 patients with de-MC relapsed posttransplant. Discussion: Serial and quantitative analysis of hematopoietic chimerism identifies those patients with the highest risk of relapse and graft rejection. It provides a reliable algorithm which justifies additional treatment to individual patients to prevent relapse or graft rejection. Initiation of prophylactic immunotherapy on the basis of in-MC offers the possibility to prevent frank hematological relapse in a great cohort of children with ALL. Most notable, no single patient who developed in-MC survived without additional treatment. The cohort of patients with in-MC clearly benefit from immunotherapy. As no patient developed fatal GVHD after additional therapy was offered escalating doses of DLI' s might be feasible to further improve outcome. However, it will be the aim of future studies to optimize treatment strategies and reveal the optimal dose of lymphocyte infusions according to the individual donor/recipient constellation.
